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Peritoneal dissemination is the primary metastatic route of ovarian cancer (OvCa), and is often accompanied
by the accumulation of ascitic fluid. The peritoneal cavity is lined by mesothelial cells (MCs), which can be
converted into carcinoma-associated fibroblasts (CAFs) through mesothelial-to-mesenchymal transition (MMT).
Here, we demonstrate that MCs isolated from ascitic fluid (AFMCs) of OvCa patients with peritoneal implants
also undergo MMT and promote subcutaneous tumour growth in mice. RNA sequencing of AFMCs revealed that
MMT-related pathways – including transforming growth factor (TGF)- signalling – are differentially regulated,
and a gene signature was verified in peritoneal implants from OvCa patients. In a mouse model, pre-induction
of MMT resulted in increased peritoneal tumour growth, whereas interfering with the TGF- receptor reduced
metastasis. MC-derived CAFs showed activation of Smad-dependent TGF- signalling, which was disrupted in OvCa
cells, despite their elevated TGF- production. Accordingly, targeting Smad-dependent signalling in the peritoneal
pre-metastatic niche in mice reduced tumour colonization, suggesting that Smad-dependent MMT could be crucial
in peritoneal carcinomatosis. Together, these results indicate that bidirectional communication between OvCa cells
and MC-derived CAFs, via TGF--mediated MMT, seems to be crucial to form a suitable metastatic niche. We
suggest MMT as a possible target for therapeutic intervention and a potential source of biomarkers for improving
OvCa diagnosis and/or prognosis.
© 2017 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd on behalf of Pathological Society of Great Britain
and Ireland.
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Introduction
A common characteristic of cancers that progress
with peritoneal metastasis is that they evolve very
rapidly, without symptoms, and are diagnosed at
advanced stages [1]. Debulking surgery followed by
platinum–taxane chemotherapy is the current standard
of treatment, and improves survival rates in selected
patients [2]; however, there is still limited scope for
curing peritoneal carcinomatosis. In particular, survival
rates of patients with ovarian cancer (OvCa) at advanced
stages are 10–30% [3], making it the fifth leading cause
of cancer death in women [4].
The peritoneum is composed of a monolayer of
mesothelial cells (MCs) that lines a connective tissue,
consisting of few fibroblasts, adipocytes, immune
cells, and vessels [5]. We have previously shown that
a subset of carcinoma-associated fibroblasts (CAFs)
in peritoneal metastases are derived from MCs via
mesothelial-to-mesenchymal transition (MMT) [6,7],
which is an epithelial-to-mesenchymal transition
(EMT)-like process [8,9]. During MMT, MCs acquire
a fibroblast-like phenotype, with increased capacity
to migrate and to invade the submesothelial compact
zone. The acquisition of mesenchymal features by MCs
results from a profound genetic reprogramming [8,9].
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CAFs are activated fibroblasts integrated in the
tumour architecture that favour cancer cell survival,
proliferation, and invasion. They synthesize an array of
extracellular matrix components (ECM), cytokines and
growth factors that contribute to the transformation of
the tumour niche and also promote angiogenesis [10].
However, the role of MC-derived CAFs in the peritoneal
tumour stroma has not been studied in depth.
At early stages, peritoneal metastasis develops as a
consequence of the accumulation of alterations in cancer
cells and a reversible mesenchymal conversion of these
cells via EMT, enabling them to detach from the primary
tumour into the peritoneal cavity [1]. However, in the
establishment of metastasis, the metastatic niche is as
important as the intrinsic features of the tumour [11].
Complex bidirectional interactions between metastatic
cancer cells and the peritoneal environment seem to be
crucial for colonization of the peritoneum, and MMT
has been recently reported to play an important role in
the processes of attaching to and invading through the
peritoneal membrane [6,12,13].
Tumours that arise in the peritoneal cavity, most
notably OvCa, often progress with an accumulation of
ascitic fluid [1]. Many cytokines and growth factors
are present in OvCa ascitic fluid [14]. In this regard,
transforming growth factor (TGF)-β is frequently found
in ascites [15], and is also a major inducer of MMT
[9]. Herein, we characterize ascitic fluid-isolated MCs
(AFMCs) from OvCa patients with peritoneal metasta-
sis in order to investigate whether they undergo MMT.
Materials and methods
Culture and treatments of MCs and OvCa cell line
Human peritoneal MCs (HPMCs) were isolated by
trypsinization of omentum samples obtained from
non-oncological patients undergoing abdominal surgery
[8]. AFMCs were obtained by centrifuging (500 g, 5
min.) peritoneal effusions of patients with International
Federation of Gynecology and Obstetrics Stage III ovar-
ian serous carcinoma. MCs were grown in Earle’s M199
medium, supplemented with 20% fetal bovine serum
(FBS) and 2% Biogro-2 (Biological Industries, Beit
Haemek, Israel). The purity of the cultures was deter-
mined by flow cytometry and/or immunofluorescence
for standard mesothelial markers, intercellular adhesion
molecule-1 and calretinin, and by ruling out any con-
tamination with endothelial cells or macrophages by
finding cultures to be negative for CD31 and CD45.
To induce MMT in vitro, HPMCs were treated with
0.5 ng/ml TGF-β1 (R&D Systems, Minneapolis, MN,
USA) plus 2.5 ng/ml interleukin (IL)-1β (R&D Systems)
(T+ I) for 72 h [8].
The human ovarian carcinoma cell line SKOV3
expressing luciferase (SKOV3-luc-D3) (Caliper Life
Sciences, Hopkinton, MA, USA) was cultured in
McCoy’s 5A medium supplemented with 10% FBS,
with geneticin used as a selection agent.
In additional experiments, HPMCs and SKOV3 cells
were stimulated with TGF-β1 (4 ng/ml; R&D Systems)
for 1 or 6 h.
Animal experiments
All experiments were performed with Swiss nu/nu
6–7-week-old female mice (Charles River Laborato-
ries, Barcelona, Spain). The experimental protocols
conformed to the National Institutes of Health Guide
for Care and Use of Laboratory Animals, and were
approved by the Animal Ethics Committee of the Unidad
de Experimentación Animal of Centro de Biología
Molecular Severo Ochoa (CBMSO) (Madrid, Spain).
Subcutaneous xenograft mouse model
In a preliminary assay, 1× 106 SKOV3-luc-D3
cells were inoculated into the left flank of mice,
or co-inoculated into the right flank with 0.5× 106
AFMCs, and tumour-produced bioluminescence was
monitored for 4 weeks. In additional experiments, mice
were co-inoculated in the left flank with a combination
of 1× 106 SKOV3-luc-D3 cells and 0.5× 106 HPMCs.
On the right flank, mice were co-inoculated with 1× 106
SKOV3-luc-D3 cells and either 0.5× 106 HPMCs T+ I
or 0.5× 106 AFMCs. Luciferase signals were monitored
for 5 weeks.
Mouse model of carcinoma peritoneal dissemination,
pre-conditioning deliveries, and treatments
To pre-condition the peritoneum, TGF-β1 expression
was induced in the peritoneal cavity with adenoviral vec-
tors. HEK 293-A cells were infected with a control ade-
novirus or with an adenovirus encoding active TGF-β1,
kindly provided by F. Rodríguez-Pascual (CBMSO,
Madrid, Spain) [16]. Four days post-infection, ade-
noviral particles were re-collected, purified with an
Adeno-X Maxi Purification Kit (Clontech Laborato-
ries, Mountain View, CA, USA), and titrated with
an Adeno-X Rapid Titer Kit (Clontech). Mice were
infected with 1× 107 infection-forming units (IFUs) of
control or TGF-β1-encoding adenovirus. Seven days
post-infection, mice were intraperitoneally inoculated
with 5× 106 SKOV3-luc-D3 cells, and tumour-produced
bioluminescence signals were monitored twice weekly
for 6 weeks.
In an additional approach to induce MMT, condi-
tioned medium from SKOV3 cells (maintained in 1%
FBS/McCoy’s 5A medium for 48 h) was centrifuged
(500× g, 5 min.) and administered intraperitoneally
to mice (n= 2). Two days later, mice were killed and
peritoneal tissue samples were fixed for immunohisto-
chemical staining. To assess the effects of interference
with TGF-β1 signalling, a total of 24 mice were treated
with either a TGF-β receptor I inhibitor (GW788388)
(3 mg/kg per day) (Tocris Bioscience, Bristol, UK)
or the vehicle dimethyl sulphoxide. Two days later,
six mice from each group received intraperitoneal
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administration of either SKOV3-conditioned medium
or control medium plus a repeat dose of TGF-β receptor
I inhibitor. Then, mice were inoculated with 5× 106
SKOV3-luc-D3 cells, and tumour growth was monitored
by bioluminescence imaging for 6 weeks.
In a preliminary assay, mice were intraperitoneally
inoculated with either phosphate-buffered saline (PBS),
1× 109 IFUs of control lentivirus, or 1× 109 IFUs
of Smad3 shRNA lentivirus, and killed 4 days later.
Smad3 knockdown was verified in peritoneal tis-
sue samples by western blotting. Then, a total of
18 mice were randomly grouped to be intraperi-
toneally infected with 1× 109 IFUs of either control or
Smad3 shRNA-producing lentiviral particles. Four days
post-infection, mice were inoculated intraperitoneally
with 5× 106 SKOV3-luc-D3 cells, and luciferase signals
were monitored for 6 weeks.
RNA sequencing and data analysis
Control HPMC and trans-differentiated AFMC samples
were lysed in TRI Reagent (Ambion, Austin, TX, USA)
to obtain total RNA. RNA integrity was checked with the
Agilent Bioanalyzer 2100 (Agilent Technologies, Santa
Clara, CA, USA). Samples were depleted of rRNA,
and RNA was then sheared into smaller fragments with
a Covaris S220 (Covaris, Woburn, MA, USA). The
cDNA library was prepared with the Beckman SPRI-
works system (Beckman Coulter, Fullerton, CA, USA).
Library fragments hybridize to complementary oligonu-
cleotides, and clusters of clones were generated in the
cBOT instrument (Illumina, San Diego, CA, USA).
Libraries were sequenced with a HiSeq 2000 (Illu-
mina). Data files from transcriptome profiling analysis
were deposited in the Gene Expression Omnibus (GEO)
repository and assigned the GEO accession number
GSE84829. Further details can be found in supplemen-
tary material, Supplementary materials and methods.
Patient samples
A total of eight ascites samples from different patients
were studied: five were analysed for MMT-related
markers, and three were used for RNA sequencing. In
addition, peritoneal metastases from 11 serous ovar-
ian carcinomas and two colon cancers were used for
immunohistochemical staining. Informed written con-
sent was obtained from the patients, with the approval
of the Ethics Committee of Hospital de la Princesa
(Madrid, Spain), Hospital de la Zarzuela (Madrid,
Spain), Hospital 12 de Octubre (Madrid, Spain) and
MD Anderson Cancer Center (Houston, TX, USA).
These studies conformed to the Declaration of Helsinki,
and were approved by the Ethics Committee of CBMSO
(Madrid, Spain).
Procedures for in vivo bioluminescence imaging,
quantitative reverse transcription polymerase chain
reaction (RT-qPCR), immunofluorescence, immuno-
histochemistry, western blotting, lentiviral production
and statistics are described in supplementary material,
Supplementary materials and methods. Specific human
primers for RT-qPCR are shown in supplementary
material, Table S1.
Results
AFMCs undergo MMT ex vivo and promote
the growth of OvCa cells in a subcutaneous
xenograft mouse model
AFMCs from OvCa patients with peritoneal implants
cultured ex vivo had a fibroblast-like morphol-
ogy, with a similar appearance to that of HPMCs
trans-differentiated in vitro. Positive immunofluores-
cence staining for calretinin confirmed their MC nature,
and α-smooth muscle actin (α-SMA) staining indicated
that AFMCs had been converted to myofibroblasts
(Figure 1A). To verify the mesenchymal conversion of
AFMCs, conventional MMT-related marker expression
was quantified by RT-qPCR. E-cadherin expression
was significantly repressed in AFMCs, and, conversely,
Snail and vascular endothelial growth factor (VEGF)
were upregulated as compared with control HPMCs
(Figure 1B).
To study the role of trans-differentiated AFMCs in
tumour growth, a subcutaneous xenograft mouse model
was used. Although SKOV3-luc-D3 cells are efficient in
establishing peritoneal metastases, a preliminary assay
showed that cancer cells alone are unable to grow when
inoculated subcutaneously (supplementary material,
Figure S1). The differential behaviour of cancer cells in
these two microenvironments suggests that MC-derived
CAFs may be key players in peritoneal metastasis.
Therefore, SKOV3-luc-D3 cells were subcutaneously
co-inoculated with control HPMCs into the left flank,
and with either in vitro or ex vivo trans-differentiated
MCs in the right flank. In both cases, tumour growth was
significantly increased in the right flank, where MCs that
had undergone MMT had been co-injected (Figure 1C).
Identification of an MMT gene signature in AFMCs
RNA sequencing analysis was carried out on AFMCs
from OvCa patients in comparison with control HPMCs.
Expression data for each gene within each sample were
used to create a heat-map for cluster classification,
which revealed a clear separation between HPMCs
and AFMCs (Figure 2A). Ensembl ID of differentially
expressed genes, i.e. those with a q-value of ≤0.05 and
at least a twofold change in expression, were submitted
to analysis with Ingenuity Pathway Analysis (IPA)
software. The analysis revealed 1997 genes that were
upregulated and 1646 genes that were downregulated in
AFMCs as compared with HPMCs. A summary of the
top 100 upregulated and top 100 downregulated genes
in AFMCs is shown in supplementary material, Tables
S2 and S3. Among the canonical pathways that were
significantly differentially regulated, many were related
to MMT/EMT and/or OvCa progression (Figure 2B).
Upstream regulators represented in our dataset were
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Figure 1. AFMCs undergo MMT ex vivo and favour tumour progression in a subcutaneous xenograft mouse model. (A) Representative
microscopy images of HPMCs, HPMCs treated with TGF-β1 plus IL-1β (T+ I), and AFMCs in culture. Under phase contrast, the altered
morphology of AFMCs is similar to that observed in HPMCs T+ I (scale bar: 100 μm). Immunofluorescence staining for calretinin (green) con-
firms the MC nature, and positive α-SMA (red) expression indicates AFMC conversion into myofibroblasts. [4′,6-Diamidino-2-phenylindole:
blue. Scale bars: 25 μm.] (B) Transcript levels of MMT markers, analysed by RT-qPCR in HPMCs (n= 8), HPMCs T+ I (n= 8), and AFMCs
(n= 5). E-cadherin expression is repressed and, conversely, the expression of Snail and VEGF is induced in AFMCs and HPMCs T+ I as com-
pared with control HPMCs. Bar graphics represent mean± standard error of the mean (SEM). Symbols represent the statistical differences
between groups (*p ≤ 0.05; **p ≤ 0.005). A.U., absolute units. (C) SKOV3-luc-D3 cells were co-inoculated with control HPMCs into the left
flank of mice, and with either HPMCs T+ I (n= 7) (a) or AFMC-derived myofibroblasts (n= 5) (b) in the right flank. Mice of both groups
were monitored for 36 days. Representative bioluminescence images show the subcutaneous growth of SKOV3-luc-D3 cells plus HPMCs
(orange circle) (a, b) as compared with SKOV3-luc-D3 cells plus HPMCs T+ I (a, blue circle) or SKOV3-luc-D3 cells plus trans-differentiated
AFMCs (b, blue circle), over the duration of the experiment. Quantification of bioluminescence showed that tumour growth was increased
in the right flank, where MCs that had undergone MMT had been used (a, b). Graphs represent mean average radiance (expressed as
photons/s/cm2/sr) of SKOV3-luc-D3 cells± SEM. Symbols represent the statistical differences between groups (**p ≤ 0.01; ****p ≤ 0.0001).
dpi, days post-inoculation.
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also identified, and, among the top upregulated ones,
we found five inducers of MMT/EMT: tumour necrosis
factor (TNF)-α, TGF-β1, IL-1β, hepatocyte growth
factor (HGF), and IL-6 (supplementary material,
Table S4).
To validate the results from the RNA sequencing
analysis, we selected five upregulated genes: three from
the top 100 [encoding matrix metalloproteinase (MMP)
1, IL-33, and early growth response 1 (EGR1)], and two
with roles in regulating the TGF-β pathway [encoding
thrombospondin 1 (TSP1) and gremlin 1 (GREM1)]
[17,18]. The interaction between these molecules
and with TGF-β1 suggests possible interesting roles
in peritoneal metastasis-related processes, including
invasion, proliferation and growth of tumour cells,
and angiogenesis (Figure 2C). Immunohistochemical
staining of these proteins in biopsies from human
OvCa peritoneal implants showed mesothelial-derived
(calretinin-positive) spindle-like cells in the stroma
tissue surrounding tumour nodules, overlapping with
areas with marked staining for MMP1, IL-33, EGR1,
TSP1, and GREM1. Adjacent tumour cells showed no
staining or variable intensity patterns for the same mark-
ers (Figure 2D). Moreover, in the mesothelial surface
(calretinin-positive) from the same biopsies, staining
was intense for MMP1, EGR1, and GREM1, and
variable for IL-33 and TSP1 (supplementary material,
Figure S2).
MMT via TGF-β1 in the peritoneum renders it more
susceptible to metastasis
It has been shown that MCs that have undergone MMT
promote increased attachment and invasion by cancer
cells [6,13]. On the basis of these observations, we
hypothesized that a peritoneum in which MMT had
taken place could be more receptive to metastasis. Given
that TGF-β1 is a key MMT inducer [16] and also
appeared as a key regulator in the RNA sequencing
data, we were interested in studying its role in peri-
toneal tumour progression. Thus, mouse peritoneum
was pre-conditioned by overexpression of TGF-β1 with
adenoviral delivery, followed by SKOV3-luc-D3 cell
intraperitoneal inoculation. Tumour growth was signifi-
cantly higher in mice whose peritoneums had been pre-
treated with TGF-β1 than in those in which a control
adenovirus had been used (Figure 3A).
We have previously reported that conditioned media
from OvCa cell cultures have a high concentration of
TGF-β1 and induce MMT in vitro [6]. Here, we observed
that pre-conditioning the peritoneum of mice for 2 days
with conditioned medium from SKOV3 cells decreased
E-cadherin expression in the mesothelial monolayer,
indicating that an early MMT had taken place (Figure
3Ba). To study the role of TGF-β1 accumulated in OvCa
ascitic fluid, mice were pretreated with a TGF-β1 recep-
tor I inhibitor (GW788388) and then with conditioned
medium from SKOV3 cells, and this was followed by
SKOV3-luc-D3 intraperitoneal delivery (Figure 3Bb).
Tumour growth was significantly higher in mice in
which an early MMT had been induced with cancer
cell medium. When TGF-β1 receptor I was inhibited
and cancer cell medium was used, tumour growth was
reduced to levels comparable to those of mice whose
peritoneums had not been pre-conditioned (Figure 3Bc).
Crosstalk between mesothelial-derived CAFs
and OvCa cells takes place via the TGF-β1–pSmad3
pathway
It is well established that TGF-β1 induces MMT through
both Smad-dependent and Smad-independent pathways
[9,19]. Smad3 is an important downstream mediator in
the Smad-dependent signalling of TGF-β1; once phos-
phorylated, pSmad3 translocates into the nucleus and
regulates gene transcription [9]. However, the response
to TGF-β1 through Smad3 has not been analysed in
MC-derived CAFs. Double immunofluorescence stain-
ing for α-SMA and pSmad3 showed that control MCs
were negative for both markers, whereas a signifi-
cant increase in the nuclear expression of pSmad3 was
observed in both in vitro and ex vivo trans-differentiated
(α-SMA positive) MCs (Figure 4A).
Analysis of the response of OvCa cells and HPMCs
to TGF-β in vitro for 1 and 6 h showed that pSmad3
was translocated to the nucleus in HPMCs, whereas it
remained cytoplasmic in OvCa cells, suggesting that the
TGF-β1–Smad3 pathway is truncated in these tumour
cells (Figure 4B).
Accordingly, we analysed pSmad3 localization in
the peritoneums of tumour-bearing mice, where CAFs
(α-SMA-positive) expressing nuclear pSmad3 were
observed in the tumour stroma and, similarly to what
was shown by our in vitro assays, pSmad3 remained
cytoplasmic in OvCa cells (supplementary material,
Figure S3).
The differential localization of pSmad3 in
MC-derived CAFs and cancer cells was also analysed by
immunohistochemistry in serial sections of peritoneal
implant biopsies from OvCa patients. The peritoneums
of control donors showed a calretinin-positive preserved
mesothelial monolayer with no staining for α-SMA or
pSmad3 (Figure 5A–C). However, in OvCa patients,
preserved mesothelial areas (calretinin-positive) dis-
tant from tumour cells showed nuclear expression
of pSmad3, indicating that the TGF-β1 pathway had
been activated (Figure 5D–F). Conversely, in the
tumour stroma, several cells with spindle-like morphol-
ogy were triple-positive for calretinin, α-SMA, and
nuclear pSmad3, confirming that MCs have activated
TGF-β–Smad3-dependent signalling, undergone an
MMT, invaded the stroma, and trans-differentiated into
CAFs (Figure 5G–I). Interestingly, OvCa peritoneal
nodules from the same patient were pSmad3-negative
(Figure 5I) or showed pSmad3 staining limited to the
cytoplasmic compartment (Figure 5J–L).
A similar localization pattern for pSmad3, nuclear in
stromal MCs but not in the tumour, was also observed in
peritoneal implants of colon cancer patients, suggesting
that a crosstalk mechanism via TGF-β1–pSmad3 could
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Figure 2. RNA sequencing analysis of AFMCs and protein validation in peritoneal metastasis biopsies. (A) Heat-map representing
the differentially expressed genes in control HPMCs (n= 3) and trans-differentiated AFMCs (n= 3). (B) Significantly differentially
regulated canonical pathways analysed with IPA software. The y-axis indicates the statistical significance, calculated by use of the
Benjamini–Hochberg correction [−log(P value)= 1.3]. The yellow threshold line represents this cut-off. (C) Interactions between five
molecules selected from upregulated genes in the dataset (MMP1, IL33, EGR1, TSP1, and GREM1) with TGF-β1 (blue lines) and
tumour-related functions (red lines). Continuous lines represent direct relationships. Dotted lines represent indirect interactions. (D) A
peritoneal implant of an OvCa biopsy reveals the presence of spindle-like cells surrounding tumour micronodules, stained for calretinin,
to indicate their mesothelial origin. Serial sections of the same case show marked staining for MMP1, IL-33, EGR1, TSP1 and GREM1
overlapping with stromal areas where mesothelial-derived fibroblastic cells accumulate. The same markers are also detected with variable
intensity within the tumour parenchyma. S, stroma; T, tumour. Scale bars: 50 μm.
be common to cancers that metastasize via peritoneal
carcinomatosis (supplementary material, Figure S4).
Knockdown of Smad3 in the peritoneum reduces
metastasis
Once the relevance of the TGF-β1–pSmad3 path-
way in the communication between OvCa cells and
HPMCs had been determined, lentiviral particles con-
taining Smad3 shRNA were administered to mice
in order to knock down its expression. In a prelimi-
nary assay, Smad3 knockdown was observable in the
peritoneums of mice 4 days after inoculation of the
lentivirus (Figure 6A). Then, lentiviral particles were
administered intraperitoneally, and this was followed by
inoculation of SKOV3-luc-D3 cells. Tumour progres-
sion was significantly reduced in mice whose peritoneal
Smad3 expression had been knocked down as compared
with controls (Figure 6Ba). Additionally, representa-
tive images showed that the number of intraperitoneal
metastases was also reduced in mice in which Smad3
was silenced as compared with controls (Figure 6Bb).
Discussion
Previous work from our group has shown that CAFs
found in peritoneal metastatic implants from patients
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Figure 3. OvCa-secreted TGF-β transforms the pre-metastatic peritoneum, favouring tumour progression. (A) Representative images
of in vivo monitoring of SKOV3-luc-D3 cells in mice pre-conditioned with TGF-β1-encoding adenovirus or control. Quantification of
bioluminescence showed that tumour growth was increased in mice pre-conditioned with TGF-β1 adenovirus (n= 6) as compared with
control adenoviral pretreatment (n= 6). (B) (a) Representative images of E-cadherin immunostaining in the mesothelial monolayer of
a mouse killed 2 days after being pre-conditioned with conditioned medium (CM) from OvCa cells or control medium. Scale bars:
25 μm. (b) Diagram of experimental design. (c) Representative images of in vivo monitoring of SKOV3-luc-D3 cells and quantification of
bioluminescence showed that intraperitoneal tumour growth was higher in mice pretreated with SKOV3 medium (CM). The TGF-β receptor
I inhibitor (GW) reduced tumour growth to levels comparable to those of mice whose peritoneums had not been pre-conditioned (control
medium). n= 6 per group. All mice were monitored for 41 days. Graphs represent mean average radiance (expressed as photons/s/cm2/sr)
of SKOV3-luc-D3 cells± standard error of the mean. Symbols represent the statistical differences over time between groups (**p ≤ 0.01;
***p ≤ 0.001; ****p ≤ 0.0001). dpi, days post-inoculation; i.p., intraperitoneal.
with abdominal cancer, such as ovarian, endometrial,
or colorectal, derive from the mesothelium, through a
tumour-induced MMT [6]. The mesenchymal conver-
sion of MCs favours adhesion, invasion and growth by
metastasizing cancer cells, through promoting profound
structural modifications of the peritoneal niche, includ-
ing matrix remodelling and angiogenesis [6,7]. Here,
we demonstrate that MCs isolated from ascitic fluid of
OvCa patients with peritoneal metastasis also undergo
MMT. Moreover, as compared with control MCs, these
trans-differentiated AFMCs favour tumour progression
in a subcutaneous xenograft mouse model, in which can-
cer cells alone did not grow. Tumour-produced factors
could continue to trans-differentiate MCs, which would
explain why control MCs also induced tumour growth,
albeit less notably. Therefore, it is tempting to specu-
late that cancer cells depend on MC-derived CAFs to
progress through the peritoneum.
RNA sequencing provided a more detailed picture
of the molecular differences, in a malignant context,
between trans-differentiated AFMCs and control MCs.
The most differentially regulated pathway was hepatic
stellate cell activation, which is in line with recent
reports of MCs being converted into hepatic stellate
cells and myofibroblasts through an MMT during liver
injury [20]. Other pathways are also relevant in the
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on behalf of Pathological Society of Great Britain and Ireland. www.pathsoc.org www.thejournalofpathology.com
Mesothelial-to-mesenchymal transition and peritoneal metastatic niche 147
Figure 4. The TGF-β1–Smad3 pathway is activated in AFMCs, and truncated in OvCa cells. (A) Double immunofluorescence staining for
α-SMA (red) and pSmad3 (green) in HPMCs T+ I and AFMCs indicates Smad3-dependent TGF-β1 pathway activation in both in vitro and ex
vivo trans-differentiated MCs as compared with double-negative control cells. Scale bars: 25 μm. pSmad3-positive nuclei were quantified;
the box plot represents mean± standard error of the mean. Symbols represent the statistical differences between groups. (B) Treatment of
HPMCs and SKOV3 cells with TGF-β1 for 1 and 6 h. Immunofluorescence images show that, upon TGF-β1 treatment, pSmad3 translocates
to the nucleus in HPMCs (a, c) and remains cytoplasmic in OvCa cells (b, d). 4′,6-Diamidino-2-phenylindole: blue. Scale bars: 25 μm.
MMT/EMT and/or OvCa metastasis context, owing to:
induction of MMT and peritoneal implantation through
OvCa-secreted molecules (TGF-β and HGF) [6,12];
regulation of MMT/EMT or the TGF-β1 pathway
[integrin-linked kinase (ILK), caveolin-1, vitamin D
receptor (VDR), thrombin, p38 mitogen-activated pro-
tein kinase (MAPK), and nuclear factor-κB (NF-κB)]
[21–27]; or protection of the peritoneal membrane from
the MMT (VDR and peroxisome proliferator-activated
receptor (PPAR) signalling) [28,29]. Interestingly,
integrin signalling is also affected, supporting previous
reports that, at initial stages of peritoneal metastasis,
MMT enhances the binding of cancer cells to the
peritoneum in a β1-integrin-dependent manner [6,13].
CAFs have been widely implicated in the remodelling
of the ECM through MMPs, which are important
molecular players in cancer progression by facilitating
tumour invasion and vascularization [30,31]. Accord-
ingly, MMP expression in OvCa has been linked to an
increased metastatic potential [32]. Additionally, there
is an increase in MMP expression during in vivo MMT
[33]. Here, we show that AFMCs have high expres-
sion of VEGF, supporting previous reports describing
MC-derived CAFs as key players in tumour stroma
vascularization [6]. In this respect, MMP and angio-
genesis pathways are differentially regulated in our
RNA sequencing data, and pro-angiogenic factors such
as VEGF, fibroblast growth factor-2, platelet-derived
growth factor, MMP1, MMP2, MMP3, MMP7 and
MMP9 appear to be upregulated in trans-differentiated
AFMCs. Many soluble cytokines are present in high
concentration in malignant OvCa ascitic fluid, including
IL-6, IL-8, IL-10, TGF-β1, VEGF, IL-1β, and TNF-α
[14,15,34,35]. On this note, IL-6, IL-8 and IL-10
pathways are also differentially regulated in our RNA
sequencing dataset and, interestingly, are associated
with OvCa progression and poor prognosis [14,34].
The inflammatory cytokines IL-1β and TNF-α have
been reported to work synergistically with TGF-β1 in
upregulating VEGF [36] and IL-6 production in MCs
[37]. Supporting this, we show that TNF-α, TGF-β1,
IL-1β and IL-6 are upstream regulators in our RNA
sequencing data, which could point to MMT as a
link between the inflammatory environment present in
ascitic fluid and peritoneal metastasis.
We validated a five-gene signature in biopsies of
OvCa patients with peritoneal metastasis, observing
that their protein products were also expressed in MCs
(calretinin-positive) with a fibroblastic phenotype sur-
rounding the tumour implants. On this note, MMP1
has been proposed to induce chemokine production in
OvCa cells, inducing angiogenesis [38]. IL-33 secreted
by CAFs is involved in promoting EMT and invasion
of head and neck squamous cancer cells [39]. TSP1 has
anti-angiogenic properties [40]; however, it also acti-
vates latent TGF-β1 [17], and its overexpression in gas-
tric carcinoma CAFs is associated with tumour growth
and nodal metastasis [41]. GREM1 has been implicated
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Figure 5. Immunohistochemical analysis of pSmad3 in human peritoneal implants of OvCa. Staining of serial sections was performed
for calretinin, α-SMA, and pSmad3. (A–C) The peritoneum of a control donor shows a preserved mesothelium (calretinin-positive)
that is negative for both α-SMA and pSmad3 markers. (D–L) Same biopsy of an OvCa patient with peritoneal metastasis. (D–F) The
preserved mesothelial monolayer (calretinin-positive and α-SMA-negative) in an area distant from the tumour implant expresses nuclear
pSmad3. (G–I) A submesothelial tumour implant shows surrounding stromal CAFs (α-SMA-positive) derived from MCs (calretinin-positive)
expressing nuclear pSmad3. (J, K) Micrometastasis area, showing OvCa cells with cytoplasmic expression of pSmad3, and stromal MCs
(calretinin-positive) expressing nuclear pSmad3. (L) Higher magnification of the delimited area in (K), where arrows point to cells with
nuclear pSmad3 staining. Insets show higher magnification of the delimited areas in (C), (F) and (I), respectively. T, tumour. Scale bars:
50 μm.
in inducing MMT and angiogenesis by inhibiting bone
morphogenetic protein (BMP)-7 [18], which has a pro-
tective role maintaining the epithelial phenotype of MCs
[42]. Finally, expression of EGR1 in stromal cells has
been considered to be an independent prognostic indi-
cator of poor survival in OvCa patients [43]. Here,
we demonstrate that the different pattern of expres-
sion observed in AFMCs reflects the changes that are
taking place in stromal MCs in the peritoneum of
OvCa patients. Further characterization of AFMCs in a
larger number of patients – and correlation with cancer
stage – could lead to a potential diagnostic and/or prog-
nostic value of the gene signature proposed here, given
that AFMCs are drained regularly by paracentesis.
TGF-β1 is a key molecule driving MMT in different
pathologies: peritoneal metastasis [6], fibrosis induced
by peritoneal dialysis [9], and formation of postsur-
gical adhesions [44]. We speculated that targeting the
TGF-β1 pathway could interfere with the accumula-
tion of mesothelial-derived CAFs, and therefore with
tumour colonization through the peritoneum. Overex-
pression of TGF-β1 in the peritoneum by adenoviral
delivery indicated that it played a role in tumour pro-
gression. On the basis of previous results [6], we have
blocked TGF-β1 receptor I in a mouse model of peri-
toneal dissemination, demonstrating that OvCa-induced
MMT, at early stages, promotes a dramatic increase in
tumour growth, whereas interfering with TGF-β sig-
nalling reduces peritoneal metastasis. These results are
supported by a previous report of in vivo TGF-β1 block-
ade reducing peritoneal metastasis and improving sur-
vival in mice [45].
Here, we show that the Smad-dependent pathway is
activated in AFMCs, based on the nuclear localization
of pSmad3, which is a necessary step for the subsequent
transcriptional regulation [9]. Interestingly, biopsies of
patients with OvCa and colorectal peritoneal implants
showed a differential localization of pSmad3 between
cancer cells and the MC-derived CAFs: cytoplasmic in
the former, and nuclear in the latter. Our results suggest
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Figure 6. Lentiviral knockdown of Smad3 reduces tumour progression in the peritoneum. (A) Western blot shows the expression level of
Smad3 in parietal peritoneum lysates of mice injected in a preliminary assay with PBS (n= 2), control lentiviral particles (n= 3), or Smad3
shRNA-producing lentiviral particles (n= 3). Expression of β-actin was employed as a loading control. (B) (a) Representative images of
SKOV3-luc-D3 cell bioluminescence in mice pre-conditioned with lentiviral particles producing Smad3 shRNA or control. Quantification of
bioluminescence showed that tumour growth was significantly reduced in mice pre-conditioned with lentiviral particles producing Smad3
shRNA (n= 9) as compared with controls (n= 9). Mice of both groups were monitored for 41 days. The graph represents mean average
radiance (expressed as photons/s/cm2/sr) of SKOV3-luc-D3 cells± standard error of the mean. Symbols represent the statistical differences
over time between both groups (**p ≤ 0.01; ***p ≤ 0.001; p ≤ 0.0001). dpi, days post-inoculation. (b) Representative images show a decrease
in the number of metastases in Smad3 knockdown mice as compared with the control group. Tumours are outlined in white.
that, despite OvCa cells producing high amounts
of TGF-β1 [6], paradoxically, the Smad-dependent
pathway appears to be disrupted. In fact, ovarian and
colorectal tumours are characterized by a frequent
loss of sensitivity to TGF-β1, owing to mutations in
its pathway [46,47]. On this note, OvCa cells have
been reported to have lower levels of Smad4 [48] or
no Smad4 translocation into the nucleus [49]. This
could explain the cytoplasmic localization of pSmad3 in
OvCa cells, given that Smad4 is necessary for this step
[9]. However, other studies have shown that OvCa cells
respond to TGF-β1 and undergo EMT with functional
Smad signalling [50,51]. Therefore, further character-
ization of the Smad-dependent and Smad-independent
pathways in both MCs and OvCa cells is needed to
shed light on this differential regulation. Here, we have
knocked down Smad3 in the peritoneums of mice,
resulting in reduced intraperitoneal tumour growth and
metastases. These data suggest that bidirectional com-
munication between OvCa cells and MC-derived CAFs,
via TGF-β–Smad-dependent signalling, could be cru-
cial to forming a suitable metastatic niche for peritoneal
carcinomatosis.
In conclusion, we propose MMT as an alternative
target in the treatment of metastases that disseminate
via the peritoneum. Strategies that interfere with MMT
in peritoneal dialysis could also be considered for the
metastasis scenario, as the effects of MMT (MC inva-
sion, fibroblast accumulation, ECM deposition, and
angiogenesis) in the peritoneum seem to be similar in
both pathologies [7]. Further analysis of the pathways
and molecules that are differentially regulated in the
MCs isolated from OvCa patients could provide insights
into novel mechanisms of peritoneal metastasis, as well
as biomarkers for improving diagnosis and/or prognosis.
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